Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET

Company Participants

David Krempa – Senior Vice President-Business Development and Investor Relations

Sean Brynjelsen – Chief Executive Officer

James Gruber – Chief Financial Officer

Conference Call Participants

Mitchell Kapoor – H. C. Wainwright

Justin Walsh – B. Riley

Operator

Good afternoon. And welcome to the Eton Pharmaceuticals’ First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request.

At this time, I’d like to turn it over to David Krempa, Senior Vice President of Business Development and Investor Relations at Eton Pharmaceuticals. Please proceed.

David Krempa

Thank you, operator. Good afternoon, everyone. And welcome to Eton’s first quarter 2022 conference call.

This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com.

Joining me on the call today, we have Sean Brynjelsen, our CEO; James Gruber, our CFO; and Kevin Guthrie, our Executive Vice President of Commercial.

In addition to taking live questions on today's call, we will be answering questions that are emailed to us. Investors can send their questions to investorrelations@etonpharma.com.

Before we begin, I would like to remind everyone that statements made during today's call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC.

Now, I will turn the call over to our CEO, Sean Brynjelsen.

Sean Brynjelsen

David, thank you. Good afternoon everyone and thank you for joining us. On today’s call I will discuss our strong first quarter commercial performance as well as some product-related development updates. Starting with the commercial results, very pleased with our revenue that we posted in the first quarter was our fifth straight quarter of sequential growth in product sales and royalty revenue. And we expect that streak of sequential growth to continue throughout the rest of this year and into the foreseeable future.

In the first quarter, we reported product sales revenue of $2.2 million, which was double what we had reported in the fourth quarter of 2021. Our revenue continues to build month-over-month Alkindi, Carglumic Acid, Biorphen all saw record revenue levels in April and are also expected to exceed those levels in May. These products are starting to gain significant traction and yet are still in the early stages of their launches.